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patients were more likely to be hospitalized (Mean: 0.51 vs. 0.37, P< 0.001) and to 
visit ER (Mean: 1.14 vs. 1.01, P< 0.001). The total annualized costs in WD group was 
significantly higher than WP group ($24,701.2 vs. $19,836.3, P< 0.001). Hospitalization 
accounted for 34.57% of total costs. After adjusting for patient characteristics, the 
patterns of differences between the two groups remain the same. ConClusions: 
Warfarin discontinuation is associated with higher number of hospitalizations and 
ER visits and higher total health care costs than warfarin persistence. Future studies 
should examine strategies to improve patient persistence with anticoagulants and 
lower total health care costs.
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objeCtives: To update the characteristics of Chinese Type 2 Diabetes Mellitus 
(T2DM) patients and describe their blood glucose control. Methods: Adelphi 
Disease Specific Programme (DSP), a cross-sectional study, collected comprehensive 
data on Chinese T2DM patients in two waves: Wave I [W1] in year 2008 and Wave 2 
[W2] in 2011-12. The patients aged ≥ 18 years were diagnosed and managed by quali-
fied internists, diabetologists or endocrinologist in 9 major cities. Chi-square test 
and Student t test were used for testing the differences between waves. Results: In 
contrast with W1 (n= 1648), W2 patients (n= 2059) were younger (mean: 56.3 vs. 57.7 
years, P< 0.001), more physically active (83% active or very active vs. 18%, P< 0.001), 
had fewer comorbidities and complications (macrovascular diseases: 10.8% vs. 
19.2%; peripheral vascular diseases: 0.8% vs. 4.0%; dyslipidemia: 22.4% vs. 42.2%; 
impaired vision: 2.3% vs. 5.6%; neuropathy: 1.4% vs. 7.0%; nephropathy: 1.7% vs. 
4.7%, all Ps< 0.0001 ), and started anti-diabetic medication (ADM) earlier (40 days of 
trying to manage lifestyle alone prior to initiating ADM vs. 64 days, P< 0.001). Of the 
insulin users, more patients in W2 than W1 were on basal insulin (28.2% vs. 12.1%, 
P< 0.05), and fewer on biphasic insulin/mixtures (51.1% vs. 59.4%, P< 0.05). Of the 
non-insulin ADM users, biguanides and sulfonylureas were the most commonly 
used agents. 2.4% and 4.2% of the patients were on GLP-1 inhibitors and DPP-4 in 
W2. W1 and W2 had the same mean of HbA1C% (7.4%). 36.6% of all the patients 
had HbA1C% < 7%. ConClusions: The data may suggest that diabetes awareness 
increased, and clinical diagnosis and medical intervention were initiated earlier for 
T2DM from 2008 to 2011-12 in China. More insulin users were treated with basal 
insulin and some started GLP-1 inhibitors and DPP-4. However, blood glucose control 
for preventing further development of complications remained to be improved.
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objeCtives: To evaluate the clinical characteristics among hypertension 
patients with diabetes in Shanghai, China. Methods: Data from a population-
based database in Minhang area including 180,806 hypertensive patients were 
examined. All hypertension cases were collected through 12 community health 
centers and then enrolled in the electronic Health Records (eHR) system. Information 
on demographics, life-style, medical records, as well as cardiovascular events was 
collected. Hypertension and diabetes were identified by ICD-10 code in the data-
base. Results: Over all, 21.6% hypertension patients had diabetes, the mean age was 
67 years old, 54.5% was female, 17.0% were current smokers and 19.7% was current 
drinkers, 17.3% had obesity, 11.3% had grade 3 hypertension, 29.8% had dislipidemia 
(high LDL-C) and 8.4% had cardiovascular events. The mean age was 69 years old for 
patients with diabetes. Among hypertension patients with diabetes, 56.7% was female, 
14.6% current smoker, 16.4% drinking, 21.6% obesity, 13.2% grade 3 hypertension, 
31.3% dislipidemia and 11.4% had cardiovascular events. ConClusions: Overall, a 
substantial proportion of hypertension patients had other cardiovascular risk factor, 
including diabetes, smoking, drinking, obesity and high LDL-C.
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objeCtives: Define the relation between nursing diagnosis and some physiologi-
cal (hemodynamic) changes during arterial hypertension. Methods: Descriptive 
study We prepared questionnaire about 5 steps of nursing activities for complet-
ing by nurses, who work in the district hospitals and family health centers and we 
collected information from this. We used SPSS17 program for analyzing results of 
survey. Collection of patients chart information made in April 2011, collection of 
nursing notes made in September 2011. Results: 1. Nurses provide just the nurs-
ing assessment stage by defining complains, and symptoms and nursing planning, 
implementation stage, but not complete sufficiently the nursing activities by nursing 
diagnosis, reassessment and conclusion after nursing procedure. 2. During the study 
collected from the nursing chart and nurses notes we defined that nurses diagnosed 
in 57.4% of patients with arterial hypertension edema, in 43.3% dyspnoea, in 14.6% 
chest pain, in 5.9% palpitation, in 1.4% cough, in 1.5% blooding from nose, in 1.5% 
confusion, 1.5% restricted movement. It shows that nurses mostly diagnosed some 
hemodynamic changes during the hypertension, but not diagnosed main criteria of 
hypertension. ConClusions: 1. It is understandable that, nursing diagnosis based 
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objeCtives: This study aimed to evaluate the incidence and risk of cardiotoxic-
ity induced by sunitinib for patients with renal cell carcinoma. Methods: This 
was a population-based case–control study that analyzed data obtained from the 
Taiwan National Health Insurance Research Database between 1 January 2000 and 
31 December 2010. All patients with renal cell carcinoma treated with sunitinib for 
the first time were included as the study cohort. Cases were identified as subjects, 
who were aged ≥ a18 years and had a first-time diagnosis of cardiovascular events 
induced by sunitinib in outpatient and inpatient settings, and matched to randomly 
selected controls by age, sex, and index date. Hazard ratios (HRs) were used to quantify 
the risk of cardiovascular events by conditional logistic regression. Results: Overall, 
187 patients with the diagnosis of Renal Cell Carcinoma (RCC)were retrieved from the 
database. A total of 17 patients treated with sunitinib as a case group and 170 patients 
did not treated with sunitinib as a control group. We found no significant difference in 
incidence of cardiotoxicity between the sunitinib cases and controls in the variables 
of diabetes, dyslipidemia and chronic periodontiti during 4-years follow-up. However 
the crude (HR= 3.71, 95% CI:1.30-10.5)and adjusted hazard ratio analysis (HR= 4.19 , 
95% CI:1.28-13.72) showed a statistical significant risk of hypertensive disease associ-
ated with sunitinib. ConClusions: Treatment with sunitinib for RCC may lead to 
hypertensive disease in Chinese population. For other cardiotoxicity, we need further 
analysis by using this large claim database beyond 2010.
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bACKGRound: Drug therapy problems (DTPs), with the associated risks inherent in 
antihypertensive and antidiabetic therapy require utmost attention. objeCtives: To 
assess the DTPs observed in the management of hypertension and diabetes mellitus 
(DM) in two tertiary health facilities in Niger Delta region of Nigeria. Methods: In 
a retrospective study, 531 randomly selected case notes of hypertensive and/or dia-
betic patients who attended the health facilities in 2011 and 2012 were evaluated for 
DTPs using Beer’s/STOPP/START criteria and selected guidelines in elderly and the 
general patients respectively. Data collected were analyzed with the aid of Statistical 
Package for Social Sciences version 20.0 and GraphPad Instat version 3.10 for win-
dows (GraphPad Software, San Diego California USA) and presented using descriptive 
statistics. Results: The mean patients’ age was 55.70±12.23 years with the elderly 
patients constituting 70.2% of the population studied. Overall, average numbers of 
drugs prescribed per prescription in the first-month and the fourth–month period of 
drug therapy considered were 4.91±1.96 and 4.92±1.70 (p>0.05) with associated mean 
DTPs values of 1.54±1.08 and 1.46±1.20 (p>0.05) respectively. Using Beer’s/STOPP/
START criteria, 21.5% and 22.8% of all DTPs at therapy initiation and last clinic visit 
were identified in the old patients. Unnecessary drug therapy was the most observed 
DTP in the first month (23.6%) and last fourth-month (29.4%) period of therapy in all 
the patients and was closely followed by wrong drug therapy (23.4%, 22.9%), need for 
additional drug therapy (20.9%, 17.4%), non-adherence to drug therapy (15.4%, 13.8%), 
and drug interactions (12.9%, 9.6%). Other DTPs observed, though to lesser extents 
were dosage too low (1.5 %, 5.2 %), adverse drug reaction (1.4 %, 1.3 %) and dosage too 
high (0.9 %, 0.4 %) respectively. ConClusions: There was high incidence of DTPs in 
the hypertensive and/or diabetic patients. Unnecessary drug therapy and wrong drug 
therapy were the most frequently observed DTPs.
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objeCtives: While discontinuation of warfarin therapy for stroke prevention is 
common in patients with atrial fibrillation, little is known about health outcomes 
associated with warfarin discontinuation. This study compared health care utiliza-
tion/costs between patients with non-valvular atrial fibrillation who were persistent 
with warfarin therapy (WP patients) and those who discontinued warfarin therapy 
(WD patients) in the US usual clinical practice setting. Methods: A retrospective 
observational study was conducted among patients (≥ 18 years of age) with non-
valvular AF who were on warfarin in the US MarketScan Database (01/2008-06/2012). 
Warfarin discontinuation was identified by a gap > 45 days in warfarin prescriptions 
within one year of warfarin initiation. A propensity score method was used to match 
WP patients and WD patients to produce compatible index dates. Patients’ follow-up 
started from the discontinuation date for WD patients and after the same duration 
of warfarin therapy for matched WP patients. Patients were followed for up to one 
year to determine the annualized number and costs of health care utilization. To 
adjust for patient characteristics, multivariate analyses were conducted. Results: 
27,000 matched patients were included for the analysis. Mean follow-up duration 
was 264 days for WD and 339 days for WP groups. Compared with WP patients, WD 
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hospitalization from heart failure, and cerebrovascular events. Logistic regression of 
potential-confounders at PD initiation was performed to determine propensity scores 
(PS), probability of prescribing colchicine. PS and covariates were controlled in multi-
variable Cox hazard regression models to investigate association of colchicine and CV 
events. Results: Of 366 subjects, 57 (15.6%) received colchicine, 75 (20.5%) had history 
of CV events. Follow-up was shorter in the non-users, 19.1 months median (range 
3.05-70.0) vs. 26.5 (3.2-71.3). CV events occurred in 7 (12.3%) in the users and 82 (26.5%) 
in the non-users. Both groups did not differ on entry Charlson co-morbidity index, 
estimated glomerular filtration rate, serum uric acid levels. Adjusted hazard ratio (HR) 
of CV events was lower in colchicine users for primary CV events (adjHR 0.28; 95% CI, 
0.09-0.90, p= 0.033), and secondary CV events (adjHR 0.29; 95% CI, 0.08-0.99, p= 0.049). 
Moreover, colchicine users had fewer CV mortality and all-causes mortality, although 
statistical significance was not found. ConClusions: Colchicine appeared to associ-
ate with reducing risk of primary and secondary CV events, and demonstrated trends 
toward lower CV mortality and all-causes mortality in PD patients.
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objeCtives: To investigate the management of hypertension in adult Malaysian 
population suffering from chronic kidney disease stage (CKD) stage 3-5. Methods: 
A retrospective, cross-sectional study was conducted on 300 patients with CKD stage 
3 (n = 98), 4 (n = 76) and 5 (n = 126) in CKD Resource Center of Hospital University 
Science Malaysia, Kelantan, Malaysia. Results: The mean age of all patients was 
58.86 ± 13.47 years and there was preponderance of male subjects (69%). The preva-
lence of hypertension was 91.3%; almost universal among the sufferers of stage 3, 
4 and 5 of CKD (87.8%, 94.7% and 92.1%, respectively). In CKD stage 5, mean systolic 
blood pressure was considerably higher than in stage 4 and 3 (p = 0.009).The per-
centage of patients with systolic BP < 130 mm Hg and diastolic BP < 80 mm Hg was 
30.3% and 49.0%, respectively. Only 24.3% of the total patients had BP < 130/80 mm 
Hg despite usingmultiple antihypertensive medications. The proportion of patients 
consuming antihypertensive drugs was as: angiotensin-converting enzyme inhibi-
tors (ACE-Is) (25%), angiotensin receptor blockers (ARBs) (14.3%),combined ACE-Is and 
ARBs (2.7%), calcium channel blockers (66.3%), β -blockers (40.7%), diuretics (60%) and 
α -blockers (14.3%). There was significantly lower percentage of patients on ACE-Is 
and ARBs in stage 5 than in stage 4 and 3 CKD patients. Proteinuria was present in 
71.7% of the patients and there was significant difference proteinuria between stage 
3, 4 and 5 (55.1 vs 59.2 vs 92.1, p = 0.000). ConClusions: Underutilization of some 
classes of anti-hypertensive medications is apparent.Higher percentage of proteinuria 
in CKD stage 5 patients may be attributed to the underuse of ACE-Is and ARBs in stage 
5.The study further indicated the need of employinginstructive efforts to get valuable 
outcomes of antihypertensive treatment in CKD sufferers.
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objeCtives: The beneficial effects of implantable cardioverter defibrillators (ICDs) 
in primary and secondary prevention patients are well established. However, data on 
potential differences between both groups in mortality and ICD therapy rates during 
long-term follow-up are scarce. The aim of the study was to assess differences in 
mortality and ICD therapy between secondary and primary prevention ICD recipi-
ents. Methods: All patients treated with an ICD, regardless of the underlying cardiac 
pathology, at the island of Crete were included in the current analysis. The study 
population was grouped by the type of prevention (secondary or primary) for sudden 
cardiac death. The primary endpoint was all-cause mortality. The secondary endpoint 
was the occurrence of device therapy (appropriate or inappropriate). Results: A 
total of 854 (88.6% men) ICD recipients were included. Of these, 623 (73%) patients 
received an ICD for primary prevention of sudden cardiac death and 231 (27%) patients 
for secondary prevention. During a mean follow-up of 12,4 +/-7,8 years, 177 (20.7%) 
patients died. The incidence of mortality was 35,5% for secondary prevention patients 
and 15.2% for primary prevention patients (p< 0.001). Ventricular arrhythmia triggered 
appropriate therapy in 91 (39,4%) secondary prevention patients. Accordingly the 
number of primary prevention patients that received appropriate therapy was 126 
(20,2%). A comparable risk for inappropriate shocks was observed. ConClusions: 
During long-term follow-up, primary prevention patients exhibited a lower risk all-
cause mortality. Both groups showed similar occurrence of inappropriate shocks but 
secondary prevention patients showed a higher rate of appropriate therapy.
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objeCtives: Catheter-based renal denervation (RDN) is a promising therapy option 
for patients with treatment resistant hypertension (TR-HTN). The RDN evidence base 
currently consists of several studies with limited sample size and variations in design, 
on subjective and objective methods of patients’ assessment. Assessment made by 
nurses with bachelor degree is different from assessment made by ordinary nurses 
(P< 0.05). 2. Assessment made by asking questions, physical examination of patients 
with arterial hypertension mostly defined symptoms of functional dysfunction of 
cardiovascular system like dyspnoea, edema, chest pain, peripheral cyanosis, hyper-
trophy left ventricular, and these symptoms can be theoretical and methodological 
aspects of nursing diagnosis. 3. Symptoms, first and secondary risk factors of arte-
rial hypertension defined by laboratory investigations, asking questions, physical 
examination (increased level of blood sugar, cholesterol, triglycerides, decreased level 
of LDLP, increased systolic and diastolic blood pressure). These findings can be theo-
retical and methodological aspects for nursing diagnosis.
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objeCtives: To evaluate the relative effectiveness of cardiac resynchronization 
therapy (CRT) versus implantable cardiac defibrillator (ICD) or optimal medical treat-
ment (OMT) in mild-moderate heart failure patients with New York Heart Association 
(NYHA) Class I and II. Methods: Randomized controlled trials of CRT, ICD and OMT 
in mild-moderate heart failure patients were identified from MEDLINE, EMBASE and 
COCHRANE database. All abstracts were identified for the search terms ‘mild-moder-
ate heart failure’, ‘CRT’, ‘ICD’, ‘OMT’ and ‘NYHA class I or II’. Abstracts were reviewed, 
and studies containing information on effectiveness profile were obtained for further 
review. Results were pooled and analyzed by a Bayesian random-effect model. The 
model used to analyze the relative effectiveness of all-cause mortality and left ventric-
ular ejection fraction (LVEF). Results: 11 studies were identified with a total of 6,865 
patients. CRT was associated with a significant reduction of the all-cause mortality 
compared with ICD alone (odds ratio 0.81, 95% credible interval 0.60 to 1.14) or OMT 
alone (odds ratio 0.59, 95% CrI 0.39 to 0.95). CRT also had a substantial improvement 
of LVEF compared with ICD treatment (mean difference 3.96, 95% CrI 0.88 to 7.08). The 
probability determined from the Bayesian analysis that CRT was the best treatment 
option was 87.2% (7.7% for ICD and 0.9% for OMT respectively). ConClusions: This 
Bayesian network meta-analysis suggests that CRT could improve the prognosis in 
patients with mild-moderate heart failure.
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objeCtives: The safety of statins had been a controversial issue. Cerivastatin was 
withdrawn due to fatal rhabdomylosis, and the high dose of simvastatin was reported 
to cause liver failure. This study aims to compare the preferences on the benefits and 
risks of statins between the patients and physicians. Methods: Discrete choice 
experiments (DCE) were conducted to measure preferences on the benefits and risks 
of statins. Two benefit parameters were defined as low-density lipoprotein cholesterol 
reduction (LDL) and myocardial infraction reduction (MI). And two risk attributes 
contained liver failure (Liv) and fatal rhabdomylosis (Rha). The questionnaires for 
the DCE were designed to satisfy orthogonality, level balance and minimum overlap. 
287 subjects (patients 205, physician 82) were participated and repeatedly evaluated 
a choice set including two hypothetical statins with different level of each attributes. 
The survey was performed by face-to-face method among Korean patients who take 
anti-hypertensive or cholesterol-lowering drug, and hospital physicians who treat 
cardiovascular disease. The data were analyzed by conditional logit (SAS 9.3 soft-
ware). Results: The physicians elicited the preferences for LDL [Mean(±SD):40.14% 
(±0.06)], MI 30.09%(±0.21), Liv 20.16%(±0.45) and Rha 9.55%(±0.29). While the patients 
estimated 38.88%(±0.15), 36.32%(±0.33), 11.55% (±0.35), 13.25%(±0.14) respectively. 
Regarding the willingness to accept risk in exchange for benefit of statins, the physi-
cians accepted risk twice than patients when the statin reduced the MI from 25% to 
40% but caused the average hepatotoxicity from 1% to 5%. ConClusions: Preference 
for the benefits of statins outweighs those of the risks in all respondents. However 
physicians consider greater importance of the Liv than the Rha while patients are 
opposite. Physicians and patients need try to narrow the perception gap regarding 
the risk of statins before starting treatment. Acknowledge This was supported by the 
grant (13182MFDS703) form Mistry of Food and Drug Safety.
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objeCtives: In peritoneal dialysis (PD) patients, remarkably high risk of cardiovascu-
lar (CV) mortality may be explained by atherosclerosis and inflammation. Colchicine 
has been illustrated to suppress inflammatory mediators via prevention of choles-
terol crystal-induced neutrophil, and reduces atherosclerosis progression. This study 
aimed to explore benefit of colchicine use on primary and secondary CV events, CV 
mortality, and all-causes mortality in PD patients. Methods: Subjects were first-
ever PD patients for ≥ 3 months, and ≥ 18 years old from January 2007 to October 
2013 in a retrospective cohort of the PD registry of Nakornping Hospital, Chiang Mai, 
Thailand. Users of colchicine for ≥ 3 months were compared to non-users. CV events 
were the composite incidence of acute myocardial infarction or unstable angina, 
